{"disease":{"id":"symptomatic-congestive-heart-failure","name":"symptomatic congestive heart failure"},"drugs":{"marketed":[{"drug_id":"enalapril-maleate","indication_name":"Symptomatic Congestive Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06973902","title":"The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Quovadis Associazione","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}